· SME · NSE
Price Band
₹326–343
Lot Size
400 shares
Issue Size
₹214 Cr
Min. Investment
₹1,37,200
Indicative, updates through the day
Cap price plus current GMP: ₹343 — arithmetic, not a forecast
Subscription data will appear once bidding opens.
Q-Line Biotec IPO is an SME issue that listed on NSE on 29 May 2026. The issue price band is fixed at ₹326–₹343 per equity share with a minimum market lot size of 400 shares, bringing the total issue size to ₹214 Cr. At the upper price band, the minimum retail application requires one lot amounting to ₹1,37,200.
No meaningful grey market premium is actively quoted for Q-Line Biotec IPO at this stage. For an SME issue at this point in the timeline, this is standard until anchor book allocations and institutional bids build volume. A missing premium is not negative sentiment; it reflects lower off-market liquidity. Read our complete guide to IPO GMP mechanics.
The minimum investment for retail investors is one lot of 400 shares (approx. ₹1,37,200 at the cut-off price). Applications must be submitted using ASBA via Net Banking or the UPI Mandate route through registered stockbrokers (Zerodha, Groww, Angel One, Upstox).
The official registrar appointed for this issue is Purva Sharegistry (India) Pvt. Ltd., with the basis of allotment finalised on 26 May 2026 and listing completed on 29 May 2026. Once declared, you can check your allotment status on our IPO Allotment Checker using your PAN or Application Number. If you are not allotted shares, the ASBA block on your bank funds is automatically released by T+2 day.
Issue Price
₹343
Listed At
₹452
Current Price
₹474.6
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, and distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through our distributor/s majorly to diagnostic service providers, hospitals and medical colleges. The company's key manufacturing segments include indigenous manufacturing of reagents (Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics, and Others [POC Devices & Rapid Tests]) and supplying/manufacturing of in-vitro diagnostics (IVD) and Pathology equipment & devices. As of December 31, 2025, the total annual capacity was about 1.4 million kits (Haematology, Clinical Chemistry, Rapid/Elisa) and 1,200 Selectra Machines. As on March 31, 2026, the company had 362 permanent employees.
Q-Line Biotec IPO raises ₹61.10 crore from anchor investors. Q-Line Biotec IPO Anchor bid date is May 20, 2026.
| Category | Shares Offered | % |
|---|---|---|
| QIB | 29,69,200 | 49.99% |
| − Anchor Investor | 17,81,200 | 0% |
| − QIB (Ex. Anchor) | 11,88,000 | 0% |
| NII (HNI) | 8,91,600 | 15.01% |
| − bNII > ₹10L | 5,94,400 | 0% |
| − sNII < ₹10L | 2,97,200 | 0% |
| Retail | 20,79,200 | 35% |
| Market Maker | 3,13,200 | 0% |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Individual investors (IND) (Min) | 2 | 800 | ₹2,74,400 |
| Individual investors (IND) (Max) | 2 | 800 | ₹2,74,400 |
| S-HNI (Min) | 3 | 1200 | ₹4,11,600 |
| S-HNI (Max) | 7 | 2800 | ₹9,60,400 |
| B-HNI (Min) | 8 | 3200 | ₹10,97,600 |
EPS (Pre IPO)
16.47
EPS (Post IPO)
22.12
ROE
16.88%
P/E (Pre IPO)
20.82
P/E (Post IPO)
15.51
Price / Book
2.44
Market Cap
₹586Cr.
| Company | P/E | ROE | Revenue |
|---|---|---|---|
| Earkart Ltd. | 20.48 | ₹49.26 Cr | |
| Galaxy Medicare Ltd. | 19.01 | ₹22.31 Cr | |
| Fabtech Technologies Ltd. | 13.32 | ₹230.30 Cr |
Q-Line Biotech Ltd. Address
Purva Sharegistry (India) Pvt. Ltd.